Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct;34(10):1783-1791.
doi: 10.1007/s00198-023-06845-0. Epub 2023 Jul 19.

Drug adherence and treatment duration for denosumab and mortality risk among hip fracture patients

Yi-Lun Tsai #  1 , Chih-Hsing Wu #  2   3 , Chia-Chun Li  2   4 , Chien-An Shih  1 , Yin-Fan Chang  2 , Jawl-Shan Hwang  5 , Ta-Wei Tai  6   7
Affiliations

Drug adherence and treatment duration for denosumab and mortality risk among hip fracture patients

Yi-Lun Tsai et al. Osteoporos Int. 2023 Oct.

Abstract

This study aimed to assess the impact of drug adherence and treatment duration for denosumab on mortality risk after hip fracture surgery. Lower all-cause mortality risk was associated with drug intervals of 7 months or less and longer treatment duration. The study highlights the importance of proper denosumab administration.

Purpose: Prescription of anti-osteoporotic medications (AOMs) after osteoporotic hip fracture may increase bone mineral density (BMD) and decrease mortality risk. However, few studies have been conducted on drug adherence and treatment duration for denosumab, a popular choice among AOMs. This study aimed to assess the impact of denosumab adherence and treatment duration on the mortality risk of hip fracture patients after surgery.

Methods: We conducted a cohort study using nationwide population data from National Health Insurance Research Database (NHIRD) in Taiwan. Patients newly diagnosed with osteoporosis and hip fracture between 2008 and 2019 who used denosumab after surgery were included. We assessed drug adherence, treatment duration, and other parameters associated with patient outcomes.

Results: A total of 21,316 patients diagnosed with osteoporotic hip fractures were included. Compared with a > 7-month drug interval for denosumab, an interval of ≤ 7 months led to lower all-cause mortality risk (hazard ratio (HR): 0.60, 95% confidence interval (CI): 0.57 ~ 0.64). Patients with denosumab treatment for over 1, 2, and 3 years had lower all-cause mortality risk (HR&CI: 0.68 (0.64 ~ 0.73), 0.48 (0.43 ~ 0.53), 0.29 (0.26 ~ 0.33)) than those with treatment duration < 1 year. Analysis after excluding short-term death yielded similar results. Analysis of causes of death also showed that good adherence and longer duration were associated with reduced mortality due to cancer and cardiovascular disease.

Conclusion: Better drug adherence and longer duration of denosumab treatment are associated with lower all-cause mortality risk among hip fracture patients after surgery. Our study highlights the benefits of a proper time interval of denosumab administration. These findings provide important insight into management of osteoporotic hip fractures and may inform clinical practice and development of guidelines.

Keywords: Adherence; All-cause mortality risk; Denosumab; Treatment duration.

PubMed Disclaimer

References

    1. Lyles KW et al. (2007) Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture. New England J Med 357(18)
    1. O’Neill TW, Roy DK (2005) How many people develop fractures with what outcome? Best Pract Res Clin Rheumatol 19(6):879–895 - PubMed - DOI
    1. Sattui SE, Saag KG (2014) Fracture mortality: associations with epidemiology and osteoporosis treatment. Nat Rev Endocrinol 10(10):592–602 - PubMed - DOI
    1. Tai TW et al. (2022) The Impact of Various Anti‐Osteoporosis Drugs on All‐Cause Mortality After Hip Fractures: A Nationwide Population Study. J Bone Mineral Res
    1. Guzon-Illescas O et al (2019) Mortality after osteoporotic hip fracture: incidence, trends, and associated factors. J Orthop Surg Res 14(1):1–9 - DOI

MeSH terms

LinkOut - more resources